For the tens of millions of people living with Long COVID, the search for effective, scalable treatments has been frustratingly slow. This large UK trial puts two promising interventions — multi-organ MRI and digital rehabilitation — through a rigorous phase 3 test, and the results challenge assumptions about what structured care can accomplish for persistent post-infectious fatigue.
The STIMULATE-ICP trial enrolled 1,152 adults across 122 primary care network clusters within six NHS Long COVID clinics in England. Participants were assigned to one of four arms: multi-organ MRI (Coverscan), a digital rehabilitation platform (Living with COVID Recovery), both interventions combined, or usual care alone. The primary endpoint was fatigue severity as measured by the Fatigue Assessment Scale (FAS) at 12 weeks. All four arms showed meaningful improvement from a baseline mean FAS of 35.8, falling to approximately 31.3 — a 4.5-point reduction. Critically, however, neither MRI nor digital rehabilitation, alone or combined, produced statistically distinguishable differences from usual care, with effect sizes hovering near zero (-0.18 for MRI vs. usual care).
This is a genuinely important null result, and it warrants careful interpretation rather than dismissal. The across-the-board improvement in all arms likely reflects a combination of natural disease trajectory, regression to the mean, and the non-specific therapeutic benefit of structured clinical engagement — what researchers sometimes call the "care effect." The finding that digital rehabilitation failed to outperform usual care is particularly notable given its lower cost and scalability potential. It suggests that symptom-driven digital tools may lack the mechanistic specificity needed to address Long COVID's heterogeneous biology, which spans neurological, immunological, and cardiovascular domains. The multi-organ MRI arm, while diagnostically informative for some patients, appears not to translate imaging data into actionable fatigue reduction at 12–24 weeks. For clinicians and health systems, this trial signals that investing in integrated pathways without targeted, mechanism-based therapies may not move the needle on patient-reported outcomes.